Total Payments
$266,281
2023 Payments
$2,761
Companies
9
Transactions
127
Medicare Patients
5,218
Medicare Billing
$378,776
Payment Breakdown by Category
Consulting$188,591 (70.8%)
Research$73,579 (27.6%)
Other$2,000 (0.8%)
Travel$1,731 (0.7%)
Food & Beverage$379.97 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $188,591 | 77 | 70.8% |
| Unspecified | $73,579 | 33 | 27.6% |
| Honoraria | $2,000 | 1 | 0.8% |
| Travel and Lodging | $1,731 | 9 | 0.7% |
| Food and Beverage | $379.97 | 7 | 0.1% |
Payments by Type
General
$192,702
94 transactions
Research
$73,579
33 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $159,753 | 65 | $0 (2021) |
| BRACCO DIAGNOSTICS INC. | $36,725 | 15 | $0 (2019) |
| GUERBET LLC | $30,746 | 13 | $0 (2023) |
| Philips Electronics North America Corporation | $15,414 | 2 | $0 (2019) |
| BioMarin Pharmaceutical Inc. | $12,070 | 23 | $0 (2023) |
| Celgene Corporation | $9,383 | 5 | $0 (2020) |
| Y-mAbs Therapeutics, Inc. | $1,105 | 2 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,040 | 1 | $0 (2020) |
| Bayer HealthCare Pharmaceuticals Inc. | $46.40 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $2,761 | 6 | Y-mAbs Therapeutics, Inc. ($1,105) |
| 2022 | $1,213 | 4 | BioMarin Pharmaceutical Inc. ($1,213) |
| 2021 | $24,172 | 12 | Merck Sharp & Dohme Corporation ($21,125) |
| 2020 | $48,201 | 21 | Merck Sharp & Dohme Corporation ($28,110) |
| 2019 | $74,163 | 25 | Merck Sharp & Dohme Corporation ($47,869) |
| 2018 | $85,386 | 41 | Merck Sharp & Dohme Corporation ($46,151) |
| 2017 | $30,385 | 18 | Merck Sharp & Dohme Corporation ($16,498) |
All Payment Transactions
127 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/21/2023 | Y-mAbs Therapeutics, Inc. | — | — | Cash or cash equivalent | $340.00 | Research |
| Study: A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | ||||||
| 07/20/2023 | Y-mAbs Therapeutics, Inc. | — | — | Cash or cash equivalent | $765.00 | Research |
| Study: A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | ||||||
| 06/06/2023 | GUERBET LLC | Elucirem (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: gadolinium-based contrast agents | ||||||
| 06/06/2023 | GUERBET LLC | Elucirem (Drug) | Food and Beverage | In-kind items and services | $156.00 | General |
| Category: gadolinium-based contrast agents | ||||||
| 03/15/2023 | BioMarin Pharmaceutical Inc. | VOXZOGO 1.2MG (Biological) | — | Cash or cash equivalent | $125.00 | Research |
| Study: A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia • Category: Achondroplasia | ||||||
| 01/25/2023 | BioMarin Pharmaceutical Inc. | VOXZOGO 1.2MG (Biological) | — | Cash or cash equivalent | $625.00 | Research |
| Study: A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia • Category: Achondroplasia | ||||||
| 11/02/2022 | BioMarin Pharmaceutical Inc. | — | — | Cash or cash equivalent | $375.00 | Research |
| Study: A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia | ||||||
| 06/22/2022 | BioMarin Pharmaceutical Inc. | — | — | Cash or cash equivalent | $338.00 | Research |
| Study: A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia | ||||||
| 03/10/2022 | BioMarin Pharmaceutical Inc. | — | — | Cash or cash equivalent | $125.00 | Research |
| Study: A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia | ||||||
| 01/06/2022 | BioMarin Pharmaceutical Inc. | — | — | Cash or cash equivalent | $375.00 | Research |
| Study: A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia | ||||||
| 06/23/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,068.00 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $161.00 | General |
| Category: ONCOLOGY | ||||||
| 05/26/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $7,016.00 | General |
| Category: ONCOLOGY | ||||||
| 05/26/2021 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $1,098.00 | General |
| 05/26/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $164.00 | General |
| Category: ONCOLOGY | ||||||
| 05/26/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $123.00 | General |
| Category: ONCOLOGY | ||||||
| 03/04/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $634.00 | General |
| Category: ONCOLOGY | ||||||
| 03/04/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $584.00 | General |
| Category: ONCOLOGY | ||||||
| 01/21/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $9,548.00 | General |
| Category: ONCOLOGY | ||||||
| 01/21/2021 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $1,349.00 | General |
| 01/21/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $827.00 | General |
| Category: ONCOLOGY | ||||||
| 01/21/2021 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 11/02/2020 | GUERBET LLC | — | — | Cash or cash equivalent | $12,952.79 | Research |
| Study: PICTURE | ||||||
| 10/22/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $489.00 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2020 | GUERBET LLC | — | — | Cash or cash equivalent | $859.94 | Research |
| Study: PICTURE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Parallel-Goup Comparison Of Two Doses Of MultiHance (0.10 mmol/kg And 0.05 mmol/kg) When Used For Magnetic Resonance Imaging (MRI) Of The Central Nervous System (CNS) | BRACCO DIAGNOSTICS INC. | $15,000 | 1 |
| Harry's Research 11 | Philips Electronics North America Corporation | $14,774 | 1 |
| PICTURE | GUERBET LLC | $14,118 | 3 |
| Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) | GUERBET LLC | $9,850 | 3 |
| CC-4047-BRN-001 - Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors | Celgene Corporation | $3,840 | 1 |
| CC-4047-BRN-01 - Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors | Celgene Corporation | $3,518 | 1 |
| Efficacy and Safety of Gadopiclenol for Central Nervous System Magnetic Resonance Imaging | GUERBET LLC | $3,460 | 2 |
| A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia | BioMarin Pharmaceutical Inc. | $1,963 | 6 |
| Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors (CC-4047-BRN-001) | Celgene Corporation | $1,380 | 1 |
| A Multicenter Multinational Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease | BioMarin Pharmaceutical Inc. | $1,200 | 4 |
| A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | Y-mAbs Therapeutics, Inc. | $1,105 | 2 |
| A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32788) IN NON-SMALL CELL LUNG CANCER | Takeda Pharmaceuticals U.S.A., Inc. | $1,040 | 1 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children with Achondroplasia, Age 0 to 60 Months | BioMarin Pharmaceutical Inc. | $546.50 | 3 |
| CC-486-NPC-001 | Celgene Corporation | $525.00 | 1 |
| A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients 18 Years of Age With CLN2 Disease | BioMarin Pharmaceutical Inc. | $500.00 | 1 |
| Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors | Celgene Corporation | $120.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,344 | 3,545 | $792,553 | $91,162 |
| 2022 | 19 | 1,409 | 4,149 | $745,824 | $100,092 |
| 2021 | 15 | 1,031 | 3,923 | $579,224 | $81,993 |
| 2020 | 22 | 1,434 | 3,871 | $702,675 | $105,530 |
Total Patients
5,218
Total Services
15,488
Medicare Billing
$378,776
Procedure Codes
103
All Medicare Procedures & Services
103 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 86 | 88 | $297,984 | $22,198 | 7.4% |
| 70450 | Ct scan head or brain without contrast | Facility | 2023 | 406 | 432 | $90,040 | $14,183 | 15.8% |
| 70553 | Mri scan of brain before and after contrast | Facility | 2023 | 106 | 109 | $54,288 | $9,497 | 17.5% |
| 70543 | Mri scan of bone of eye socket, face, and/or neck before and after contrast | Office | 2023 | 20 | 20 | $56,135 | $6,149 | 11.0% |
| 72125 | Ct scan of upper spine without contrast | Facility | 2023 | 126 | 128 | $36,224 | $4,971 | 13.7% |
| 70551 | Mri scan of brain without contrast | Office | 2023 | 26 | 26 | $47,630 | $4,227 | 8.9% |
| 70496 | Ct scan of blood vessels of head with contrast | Facility | 2023 | 58 | 59 | $25,603 | $4,113 | 16.1% |
| 70498 | Ct scan of blood vessels of neck with contrast | Facility | 2023 | 60 | 60 | $26,046 | $4,056 | 15.6% |
| 70450 | Ct scan head or brain without contrast | Office | 2023 | 29 | 29 | $20,706 | $2,537 | 12.3% |
| 70486 | Ct scan of face without contrast | Office | 2023 | 21 | 21 | $19,047 | $2,168 | 11.4% |
| 70551 | Mri scan of brain without contrast | Facility | 2023 | 37 | 37 | $12,592 | $2,164 | 17.2% |
| 70491 | Ct scan of soft tissue of neck with contrast | Office | 2023 | 11 | 11 | $12,364 | $1,617 | 13.1% |
| 70486 | Ct scan of face without contrast | Facility | 2023 | 45 | 45 | $12,317 | $1,493 | 12.1% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Facility | 2023 | 46 | 46 | $14,352 | $1,472 | 10.3% |
| 70543 | Mri scan of bone of eye socket, face, and/or neck before and after contrast | Facility | 2023 | 17 | 18 | $6,830 | $1,415 | 20.7% |
| 70491 | Ct scan of soft tissue of neck with contrast | Facility | 2023 | 24 | 25 | $8,029 | $1,321 | 16.5% |
| 72157 | Mri scan of middle spinal canal before and after contrast | Facility | 2023 | 13 | 13 | $6,610 | $1,171 | 17.7% |
| 70544 | Mri scan of blood vessels of head without contrast | Facility | 2023 | 24 | 24 | $7,021 | $1,168 | 16.6% |
| 72156 | Mri scan of upper spinal canal before and after contrast | Facility | 2023 | 12 | 12 | $6,230 | $1,075 | 17.3% |
| 72158 | Mri scan of lower spinal canal before and after contrast | Facility | 2023 | 12 | 12 | $5,928 | $1,074 | 18.1% |
| 72148 | Mri scan of lower spinal canal without contrast | Facility | 2023 | 13 | 13 | $2,913 | $711.24 | 24.4% |
| 72141 | Mri scan of upper spinal canal without contrast | Facility | 2023 | 12 | 12 | $3,924 | $702.24 | 17.9% |
| 72131 | Ct scan of lower spine without contrast | Facility | 2023 | 16 | 17 | $4,627 | $662.55 | 14.3% |
| 72132 | Ct scan of lower spine with contrast | Facility | 2023 | 14 | 14 | $4,732 | $658.16 | 13.9% |
| A9585 | Injection, gadobutrol, 0.1 ml | Office | 2023 | 92 | 737 | $7,370 | $188.47 | 2.6% |
About Doris Lin, M.D., PH.D
Doris Lin, M.D., PH.D is a Diagnostic Radiology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245274208.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Doris Lin, M.D., PH.D has received a total of $266,281 in payments from pharmaceutical and medical device companies, with $2,761 received in 2023. These payments were reported across 127 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($188,591).
As a Medicare-enrolled provider, Lin has provided services to 5,218 Medicare beneficiaries, totaling 15,488 services with total Medicare billing of $378,776. Data is available for 4 years (2020–2023), covering 103 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Baltimore, MD
- Active Since 06/16/2006
- Last Updated 02/11/2013
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1245274208
Products in Payments
- KEYTRUDA (Biological) $159,753
- ProHance (Drug) $20,457
- LUMASON (Drug) $15,000
- Achieva 3.0T R5 (Device) $14,774
- Pomalyst (Drug) $8,858
- DOTAREM (Drug) $2,412
- Brineura (Biological) $1,100
- MULTIHANCE (Drug) $956.57
- Elucirem (Drug) $906.00
- VOXZOGO 1.2MG (Biological) $750.00
- Ingenia 3 0T R5 (Device) $640.00
- BMN 190 (Biological) $600.00
- BMN 111 (Biological) $546.50
- CC-486 (Drug) $525.00
- PROHANCE (Drug) $311.41
- Gadavist (Drug) $46.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Baltimore
Dr. Florence Doo, M.d, M.D
Diagnostic Radiology — Payments: $142,421
Diagnostic Radiology $142,421
Nariman Nezami, Md, MD
Diagnostic Radiology — Payments: $138,378
Diagnostic Radiology $138,378
Dr. Charles White, Md, MD
Diagnostic Radiology — Payments: $123,627
Diagnostic Radiology $123,627
Dr. Atif Zaheer, Md, MD
Diagnostic Radiology — Payments: $117,328
Diagnostic Radiology $117,328
Karen Horton, M.d, M.D
Diagnostic Radiology — Payments: $105,131
Diagnostic Radiology $105,131
Neal Halsey, M.d, M.D
Diagnostic Radiology — Payments: $98,470
Diagnostic Radiology $98,470